Managing the Disease and Symptoms Simultaneously within Multiple Sclerosis Patients
This Medical Meeting Reporter will review and analyze data presented at the 67th Annual American Academy of Neurology Meeting. This program will review pertinent data released at the meeting and educate healthcare professionals on the best way to apply this data to their practice. New and emerging therapies and their safety and efficacy data will be discussed. Faculty will discuss diagnostic techniques as well as the pathophysiology of multiple sclerosis. Physicians will be given up-to-date techniques on how to manage the disease and symptoms of MS simultaneously and be able to provide personalized treatments plans for their patients in practice.
Neurologists and other healthcare professionals responsible for the diagnosis, treatment or management of patients with multiple sclerosis.
Upon completion of this activity, participants will be able to:
- Discuss the pathophysiology of multiple sclerosis, including the origins of acute exacerbations.
- Examine new and emerging therapies in multiple sclerosis, and their safety and efficacy data.
- Personalize and inform multiple sclerosis treatment plans with the integration of patient data.
Clyde E. Markowitz, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Relationship Identified With:
Clyde E. Markowitz, MD
Consultant/Advisor: Acorda Therapeutics, Inc.; Bayer AG; Biogen Idec; EMD Serono; F. Hoffman- La Roche Ltd.; Genentech; Novartis AG; ONO Pharmaceutical Co. Ltd.; Sanofi; Teva Pharmaceutical Products Ltd.
Edward J. Fox, MD, PhD
Consultant/Advisor: Acorda Therapeutics Inc.; Bayer AG; Biogen Idec; Chugai Pharmaceutical Co., Ltd.; Eli Lilly and Company; EMD Serono, Inc.; F. Hoffman- La Roche Ltd.; Genzyme Corporation; Novartis AG; ONO Pharmaceutical Co. Ltd.; Opexa Therapeutics, Inc; Sanofi; Teva Pharmaceutical Products Ltd.
Planners, Managers, Reviewers: Sandy Breslow; Brynne Hunter; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Jaimie Kelly; and Bernard Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Co-provided by the Elsevier Office of Continuing Medical Eduation and AcademicCME
Course Open Date: July 24, 2015 | Course Expiration Date: July 23, 2016
Credit Designation Statement
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Mallinckrodt Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, AcademicCME and Mallinckrodt Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician